Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.4616
-0.0344 (-6.94%)
At close: Dec 5, 2025, 4:00 PM EST
0.4727
+0.0111 (2.40%)
After-hours: Dec 5, 2025, 7:46 PM EST
Cosmos Health Revenue
Cosmos Health had revenue of $17.11M in the quarter ending September 30, 2025, with 37.86% growth. This brings the company's revenue in the last twelve months to $59.79M, up 6.69% year-over-year. In the year 2024, Cosmos Health had annual revenue of $54.43M with 1.97% growth.
Revenue (ttm)
$59.79M
Revenue Growth
+6.69%
P/S Ratio
0.21
Revenue / Employee
$401,294
Employees
149
Market Cap
16.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.43M | 1.05M | 1.97% |
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
COSM News
- 3 days ago - Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets - GlobeNewsWire
- 4 days ago - Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases - GlobeNewsWire
- 19 days ago - Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M - GlobeNewsWire
- 5 weeks ago - Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy - GlobeNewsWire
- 6 weeks ago - Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million - GlobeNewsWire
- 7 weeks ago - Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million - GlobeNewsWire
- 2 months ago - Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility - GlobeNewsWire
- 2 months ago - Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units - GlobeNewsWire